Internal Medicine

Charlson Comorbidity Index (CCI) Calculator

Q: Charlson vs CIRS — which to use?

Charlson is shorter, simpler, and validated for survival prognosis. CIRS is more detailed (rated across 14 organ systems) and better suited for comprehensive geriatric assessment.

Q: Does inactive cancer count?

It depends on stage and time since remission. Active cancer scores 2 points, metastatic disease scores 6. Remission > 5 years is often not counted, but the decision is individualized.

Overall burden of comorbid disease and survival prognosis

Primary source: Charlson ME et al. J Chronic Dis 1987; 40(5): 373-383

Aleksandr A. Aulov, MD, internal medicine Last clinical review: April 28, 2026

Online calculation

Myocardial infarction (history of)

Congestive heart failure

Peripheral vascular disease

Cerebrovascular disease

Dementia

Chronic pulmonary disease

Connective tissue disease

Peptic ulcer disease

Mild liver disease (no cirrhosis, cholestasis)

Diabetes mellitus without end-organ damage

Diabetes with end-organ damage

Hemiplegia

Moderate/severe chronic kidney disease

Malignancy (localized)

Metastatic solid tumor

Severe liver disease (cirrhosis, portal hypertension)

AIDS / HIV infection with severe immunodeficiency

Age adjustment

About this score

The Charlson Comorbidity Index (Charlson ME et al, J Chronic Dis 1987) is a standard measure of comorbid disease burden and 10-year survival prognosis. It includes 19 conditions with different point weights (1–6): MI, CHF, peripheral vascular disease, stroke, dementia, COPD, connective tissue disease, peptic ulcer disease, mild liver disease, diabetes (with/without complications), hemiplegia, CKD, tumor (solid and metastatic), leukemia, lymphoma, severe liver disease, AIDS.

An age adjustment is added to the base index: +1 point for each decade after age 50. Total score 0+. Interpretation of 1-year mortality: 0 — 12%, 1–2 — 26%, 3–4 — 52%, ≥ 5 — 85%. 10-year survival: 0 points — 99%, 1 — 96%, 2 — 90%, 3 — 77%, 4 — 53%, ≥ 5 — < 21%.

Used as a universal comorbidity profile in clinical research and for outcome prediction in patients with severe multimorbidity. Particularly useful in oncology (choosing aggressive vs palliative management), surgery (procedural risk), and geriatrics.

When to use

Estimating expected life expectancy in a patient with multiple comorbidities.
Deciding whether aggressive interventions are warranted (oncologic surgery, screening).
Stratification in clinical studies to control for comorbidity.
Geriatric assessment before major decisions (transplantation, ART, device implantation).

Clinical example

Case

A 72-year-old man with three comorbidities: history of MI (1), stage 4 CKD (2), diabetes with diabetic retinopathy and nephropathy (2). 40-year smoking history.

Calculation

MI (1) + severe CKD (2) + diabetes with end-organ damage (2) + age adjustment for 70+ years (3, +1 for each decade after 50) = 8 points.

Interpretation and management

High comorbidity index (≥ 5). 10-year survival prognosis is low (< 21%), 1-year mortality is high (~85% with a concurrent acute illness). Management: reprioritize care — aggressive interventions are justified only if they meaningfully improve quality of life. Cancer screening (colonoscopy, mammography) is often not indicated when life expectancy is < 10 years. Focus shifts to symptomatic treatment and control of underlying conditions.

Limitations and cautions

Does not account for the severity of a given condition within its category (diabetes with one microvascular complication vs all three).
Does not reflect functional status (ECOG, ADL) — two patients with the same Charlson score can have very different quality of life.
Prognostic estimates were derived decades ago — current mortality for most conditions is lower.
Does not account for socioeconomic factors.

Frequently asked questions

Charlson vs CIRS — which to use?

Charlson is shorter, simpler, and validated for survival prognosis. CIRS is more detailed (rated across 14 organ systems) and better suited for comprehensive geriatric assessment.

Does inactive cancer count?

It depends on stage and time since remission. Active cancer scores 2 points, metastatic disease scores 6. Remission > 5 years is often not counted, but the decision is individualized.

Is it applicable in younger patients?

Yes, the base index applies at any age. The age adjustment is added only after age 50.

Does the score change over time?

Yes, as new diagnoses are added and the patient ages. It should be recalculated when there is a significant change in status (new MI, CKD stage progression, new metastases).

All clinical calculators in one place

Validated scores and formulas with full interpretation, clinical examples and source references. Open access, no registration required.

65+ calculators · scores and formulas · interpretation with management notes

Browse all calculators

АА

Aleksandr A. Aulov Physician, internal medicine, Sechenov School — independent medical education platform. Calculators are compiled from the original publications and current clinical guidelines. Interpretation thresholds follow the source study unless stated otherwise.

This calculator is intended for healthcare professionals. Do not use it for self-diagnosis or self-treatment. Management decisions are made by the treating clinician based on the full clinical picture of the individual patient.